Xencor Inc (XNCR)
NASDAQ:XNCR
Want to see XNCR full AI Analyst Report?
XNCR Stock Chart & Stats
$13.06
-$0.21(-0.88%)
At close: 4:00 PM EST
$13.06
-$0.21(-0.88%)
Day’s Range― - ―
52-Week Range$6.92 - $18.69
Previous CloseN/A
Volume126.93K
Average Volume (3M)882.32K
Market Cap
$960.74M
Enterprise Value$1.02B
Total Cash (Recent Filing)$547.73M
Total Debt (Recent Filing)$187.75M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 13, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding73,338,640
10 Day Avg. Volume794,312
30 Day Avg. Volume882,317
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue8.16
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda-21.71
Forecast
1Y Price Target
$24.72Price Target Upside89.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$120.68M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FundingAnalyst points out a strong cash position and anticipated royalty income from an Xtend patent extension, which should provide funding to execute pivotal studies.
Clinical Development MilestonesAnalyst highlights that updated Phase I data for lead T‑cell engager programs XmAb819 and XmAb541 will guide Phase III dose selection, a critical step to initiate pivotal studies.
TL1A Program MomentumAnalyst notes that clinical and preclinical TL1A data will be presented at a major conference and that the ongoing Phase IIb XENITH‑UC study continues to enroll, supporting program momentum.
Bears Say
Competitive PressuresAnalyst cautions that competing combination therapies and rising competition against TL1A‑targeted programs increase pressure on lead candidates to demonstrate clear differentiation and superior value.
Intellectual Property And RoyaltiesAnalyst warns that a disagreement over the Ultomiris patent limits expected royalties to ex‑U.S. sales and reduces the company's cash runway.
Trial Execution And Safety RiskAnalyst reports a dosing‑preparation error that increased early adverse effects and likely reduced efficacy, creating uncertainty around trial outcomes and development decisions.
Xencor News
XNCR FAQ
What was Xencor Inc’s price range in the past 12 months?
Xencor Inc lowest stock price was $6.92 and its highest was $18.69 in the past 12 months.
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is $960.74M.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is May 13, 2026 which is in 14 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on Feb 25, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.601 by $0.511.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.67.
How many shares outstanding does Xencor Inc have?
Xencor Inc has 73,338,640 shares outstanding.
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.601. Following the earnings report the stock price went up 13.105%.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in XNCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.72 (89.26% Upside)
$24.72 (89.26% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 456.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $570.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.63%
12-Months-Change
Fundamentals
Return on Equity
-14.58%
Trailing 12-Months
Asset Growth
-8.03%
Trailing 12-Months
Company Description
Xencor Inc
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
XNCR Stock 12 Month Forecast
Average Price Target
$24.72
▲(89.26% Upside)
Technical Analysis
Dianthus Therapeutics
―
Autolus Therapeutics
―
Stoke Therapeutics
―
Relay Therapeutics
―
Maravai Lifesciences Holdings
―
Ownership Overview
1.56% Insiders
29.95% Mutual Funds
0.63% Other Institutional Investors
42.46% Public Companies and
Individual Investors